Roche Gets FDA Approval for Subcutaneous Formulation of Tecentriq
The FDA approves subcutaneous formulation of RHHBY's leading immunotherapy drug, Tecentriq, under the brand name Tecentriq Hybreza.
| Ticker |
Sentiment |
Impact |
|
LLY
|
Neutral
|
21 %
|
|
HALO
|
Neutral
|
7 %
|
